← All trials
NCT07300150
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2025
- Primary completion
- Oct 18, 2028
- Completion date
- Oct 18, 2028
- First posted
- Dec 23, 2025
- Last posted
- Dec 23, 2025
- Enrollment
- 195
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PAQ Therapeutics, Inc.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.